Ovarian cancer is an aggressive disease, and only a few cases are diagnosed at earlystages due to the absence of symptoms. Τhe majority of malignant ovarian tumors (>90%) are ofepithelial origin and are subdivided into five histological sub types according to differentmolecular pathogenesis and clinical behavior. High-grade serous ovarian cancer is the mostcommon subtype (70%). However, the different histotypes of ovarian cancer should be viewed asseparate diseases both clinically and in biomarker studies. At present, surgical debulking andplatinum/taxane - based chemotherapy is the standard of care for epithelial ovarian cancer.Most patients show an initial response to this therapeutic approach, but the majority of them experiencedisease recurrence at which point cure is no longer possible, due to acquired resistance inthose chemotherapeutic regimens. Nevertheless, the current treatment model is still a “one-sizefits-all” approach. Epigenetic modifications represent heritable modifications in gene expressionwithout alteration of the DNA sequence. DNA methylation is the best-studied epigenetic mechanism,and in epithelial ovarian cancer, the methylenome is widely altered. In addition, patterns ofDNA methylation may represent potential diagnostic and prognostic markers as well as markerspredictive of chemoresistance and potential therapeutic targets. This article systematically reviewsthe complex area of DNA methylation in ovarian carcinoma and summarizes the current implicationsand future perspectives of its use as a screening, diagnostic, prognostic and predictive tool aswell as in personalized cancer therapy.